Structure Therapeutics reports Q4 2022 net loss $11.9M; GSBR-1290 Phase 1b dosing complete

Structure Therapeutics Inc.

Completed dosing of GSBR-1290 Phase 1b in healthy overweight volunteers; topline data from Phase 1b and Phase 2a expected 2H 2023.
Completed $185.3M upsized IPO in Feb 2023; net proceeds ~$166.7M; cash position $249.4M as of Feb 28, 2023.
Cash, cash equivalents and marketable securities $90.8M at Dec 31, 2022; expects to fund operations through end of 2025.
Net loss $11.9M Q4 2022 vs $13.4M Q4 2021; full year net loss $51.3M vs $38.0M in 2021.
R&D expenses $8.4M Q4 2022, $36.2M full year; G&A $4.6M Q4, $16.4M full year.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.